Drug Delivery Platforms
•95 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (95)
%
| Company | Market Cap | Price |
|---|---|---|
|
Drug Delivery Platforms reflect Merck's platform technologies for targeted, controlled-release therapies.
|
$200.78B |
$79.96
-0.16%
|
|
Drug Delivery Platforms capture the long-acting injectable/extended-release capabilities central to GSK's HIV and RI&I strategies.
|
$88.43B |
$21.73
|
|
The company emphasizes delivery technology for RNAi (e.g., GalNAc conjugates, LNPs) to achieve tissue targeting and infrequent dosing, i.e., Drug Delivery Platforms.
|
$60.04B |
$460.46
+0.04%
|
|
INGREZZA sprinkle formulation represents a drug-delivery platform/format to improve administration and accessibility.
|
$14.51B |
$146.95
+0.38%
|
|
The company emphasizes differentiated drug delivery platforms (e.g., intrathecal, subcutaneous administration) as a core capability for antisense programs.
|
$11.14B |
$69.97
-0.04%
|
|
Aptar's core offering is drug delivery platforms, including nose-to-brain and inhaled delivery systems (e.g., Precision Nasal 3, Quotri DPIs).
|
$8.65B |
$130.93
-0.01%
|
|
Drug Delivery Platforms capture the core platform technology enabling multiple high-value containment/delivery products.
|
$7.22B |
$23.85
-0.58%
|
|
Drug Delivery Platforms – AOC is a delivery technology that targets oligonucleotide payloads to tissues.
|
$5.18B |
$42.95
+3.74%
|
|
Alkermes relies on proprietary drug-delivery platforms (e.g., LinkeRx, NanoCrystal, polymer-based microsphere for VIVITROL) as core differentiators.
|
$5.15B |
$31.21
-0.54%
|
|
Represents the drug-delivery platform / formulation technology aspects associated with EFX (biologic delivered via syringe).
|
$4.30B |
$53.88
-0.39%
|
|
Drug delivery platforms underpin complex biologics (ADCs, immunocytokines) and enable advanced formulations.
|
$3.43B |
$31.62
+0.86%
|
|
Ligand's Captisol and NITRICIL platforms are proprietary drug-delivery technologies that Ligand licenses to partners, representing a direct product/platform offering.
|
$3.43B |
$177.73
-2.16%
|
|
The company’s infusion-pump platform (Plum Duo/Solo/360) and related delivery technology fit the Drug Delivery Platforms category.
|
$3.01B |
$119.67
-0.24%
|
|
LockBody functions as a targeted drug-delivery platform to limit activity to diseased tissue.
|
$2.98B |
$22.31
-2.75%
|
|
Uses proprietary drug-delivery platform technologies (extended-release formulations) as a differentiation in products.
|
$2.74B |
$49.00
-0.79%
|
|
Denali's TransportVehicle (TV) platform is a proprietary drug delivery platform designed to cross the blood-brain barrier, representing a major Drug Delivery Platforms investable theme.
|
$2.23B |
$15.37
-5.12%
|
|
ELUTYX is a proprietary drug-delivery platform powering sustained release, underpinning AXPAXLI, a core retinal program.
|
$1.94B |
$12.48
+1.88%
|
|
VRDN-003 and related programs leverage drug delivery platform technology to extend half-life and dosing convenience.
|
$1.71B |
$20.99
-3.94%
|
|
LUMRYZ utilizes a proprietary drug-delivery platform (extended-release, once-nightly) core to Avadel's product strategy.
|
$1.51B |
$15.49
-0.61%
|
|
The Cloudbreak platform represents a drug delivery platform technology (Drug Delivery Platforms) used to create Drug-Fc Conjugates with extended half-life for therapeutics.
|
$1.47B |
$113.05
-2.88%
|
|
NUV-1511 is a Drug-Drug Conjugate platform, a proprietary drug delivery platform the company uses for targeted therapy.
|
$1.27B |
$3.74
-1.84%
|
|
Neffy is a needle-free intranasal delivery drug using a proprietary delivery platform, representing a major drug delivery platform product.
|
$1.11B |
$11.32
-3.25%
|
|
PEGylation-based drug delivery platform used to optimize pharmacokinetics and enable new therapeutics.
|
$1.08B |
$58.85
+2.65%
|
|
DURAVYU uses EyePoint's Durasert E sustained-delivery platform, a core drug delivery technology.
|
$956.48M |
$13.90
+4.91%
|
|
LSD-derived MM120 uses a proprietary oral disintegrating tablet (ODT) formulation and delivery platform.
|
$892.28M |
$11.81
-5.75%
|
|
OPTIREACH is a proprietary drug-delivery platform enabling non-invasive topical delivery to the back of the eye.
|
$884.62M |
$21.09
-1.91%
|
|
PRO-XTEN represents a protease-cleavable masking drug-delivery platform underlying the T-cell engager assets.
|
$758.93M |
$5.49
+5.98%
|
|
Drug delivery platforms and integration with medical devices are a facet of KE's Medical CMO capabilities.
|
$729.22M |
$29.91
+1.08%
|
|
GH001/GH002 involve novel drug-delivery platforms (inhalation and IV) to enable rapid-onset psychedelic therapies.
|
$655.03M |
$12.59
-4.48%
|
|
Aquestive's PharmFilm/Adrenaverse drug delivery platform enables non-invasive dissolvable oral films (Anaphylm, Libervant) and supports pipeline products like AQST-108.
|
$649.60M |
$6.54
-2.24%
|
|
Drug Delivery Platforms captures Kodiak's platform-based delivery approach for extended intravitreal duration.
|
$626.30M |
$11.87
-11.42%
|
|
Zevra's Ligand Activated Technology (LAT) represents a drug delivery platform used to create prodrugs with improved PK/PD and safety, fitting Drug Delivery Platforms.
|
$602.02M |
$11.01
+0.18%
|
|
Molgramostim is delivered via a drug-delivery platform (inhalation system), linking to drug delivery platform technologies.
|
$582.46M |
$3.37
-1.75%
|
|
MBX uses a platform-based approach to extend action durations and improve delivery, aligning with Drug Delivery Platforms as an investable theme.
|
$557.85M |
$16.69
-0.36%
|
|
PROTAC platform acts as a drug delivery/platform approach enabling targeted protein degradation across assets.
|
$548.90M |
$7.52
-2.59%
|
|
NAVXpress is REGENXBIO's in-house drug delivery platform enabling scalable production for RGX-202 and other programs.
|
$547.75M |
$10.92
-9.83%
|
|
Modifier gene therapy platform functions as a drug delivery platform (AAV-based).
|
$516.90M |
$1.79
+1.41%
|
|
Platform includes proprietary delivery components (capsids, microdystrophin constructs) and manufacturing optimization that underpin its gene therapies.
|
$461.99M |
$5.96
-7.31%
|
|
DDX platform is a proprietary drug delivery platform enabling localized, genetic medicines.
|
$428.77M |
$8.39
-5.20%
|
|
The company markets a proprietary ADC drug-delivery platform (payloads, linkers, conjugation chemistries) central to its products and pipeline.
|
$404.65M |
$4.36
+6.86%
|
|
Drug Delivery Platforms: The program employs GalNAc-mediated liver targeting and subcutaneous administration, indicating a core delivery platform component.
|
$403.51M |
$42.97
-8.18%
|
|
The company emphasizes a proprietary drug delivery and formulation platform (e.g., thaw-and-inject, scalable manufacturing) that supports cell therapies, aligning with Drug Delivery Platforms.
|
$385.92M |
$1.69
-1.74%
|
|
Delcath markets a drug delivery platform (HEPZATO KIT) for liver-directed chemotherapy, fitting the 'Drug Delivery Platforms' investable theme.
|
$374.21M |
$10.74
-0.78%
|
|
Drug delivery platform: Perspective aims to deliver alpha emitters via targeted constructs (peptides) as a therapeutic platform.
|
$360.75M |
$4.86
+15.71%
|
|
Delivery platform for gene therapies (vector-based delivery) qualifies as Drug Delivery Platforms.
|
$351.23M |
$3.27
+0.46%
|
|
Viral vectors are used as a drug-delivery platform for intratumoral administration.
|
$310.14M |
$6.19
-6.07%
|
|
Viaskin uses a patch-based epicutaneous delivery approach, representing a Drug Delivery Platforms category.
|
$289.50M |
$15.00
-3.29%
|
|
Proprietary drug delivery platform using plant virus–derived nanoparticles fits Drug Delivery Platforms.
|
$280.13M |
$0.70
|
|
PROBODY represents a drug delivery platform enabling conditional/targeted activity.
|
$266.05M |
$3.30
+1.23%
|
|
Lifecore's proprietary HA manufacturing and sterile fill/finish capabilities constitute a Drug Delivery Platform capability.
|
$240.66M |
$6.50
-2.40%
|
|
Core drug delivery platform enabling intracellular delivery of therapeutics across multiple programs.
|
$231.14M |
$6.09
-10.44%
|
|
Utilizes a proprietary drug delivery platform to target therapeutics to brain tumors, bypassing the blood-brain barrier.
|
$219.38M |
$11.53
-1.11%
|
|
Direct product platform: a polymer-based micro-sphere drug delivery platform enabling local, extended-release therapeutics (Diffusphere) used in EP-104IAR and EP-104GI.
|
$216.23M |
$6.07
-1.78%
|
|
Intranasal drug delivery platform for Foralumab is a drug delivery technology the company directly develops and uses.
|
$210.30M |
$2.04
-5.56%
|
|
Emrosi employs a modified/extended-release drug formulation, indicating a drug delivery platform capability.
|
$169.83M |
$7.29
+0.41%
|
|
STAC-BBB is a delivery platform for CNS-targeted therapies, representing a standalone drug delivery platform.
|
$156.76M |
$0.67
-10.35%
|
|
PepGen's core differentiator is the Enhanced Delivery Oligonucleotide (EDO) platform, a drug-delivery platform for oligonucleotide therapies.
|
$154.28M |
$4.71
-3.78%
|
|
The HA platform enables localized, potentially controlled-release regenerative therapies.
|
$131.49M |
$9.12
-1.51%
|
|
Drug Delivery Platforms: TCR-T engineering is a platform approach to delivering cell-based therapies (non-viral delivery).
|
$125.07M |
$2.21
+0.45%
|
|
Entera's N-Tab oral delivery platform is the core technology enabling the oral administration of large-molecule peptides, representing a primary platform product category.
|
$120.45M |
$2.65
+6.00%
|
|
Drug delivery platform enabling rapid nose-to-brain action with non-systemic administration (pherines).
|
$117.51M |
$4.03
-4.73%
|
|
MGX's platform includes delivery capabilities (e.g., single-vector AAV packaging), aligning with drug delivery platforms.
|
$106.91M |
$2.86
-8.04%
|
|
Sympazan PharmFilm technology and overall drug-delivery differentiation reflect Drug Delivery Platforms.
|
$79.98M |
$0.83
-4.47%
|
|
Proprietary oral vaccine delivery platform (VAAST) enabling needle-free administration and mucosal immunity.
|
$79.22M |
$0.35
-1.41%
|
|
NDV-01 is a sustained-release drug-delivery platform (Gemcitabine/Docetaxel intravesical formulation), fitting Drug Delivery Platforms.
|
$67.71M |
$2.04
-8.93%
|
|
RAP Platform described as a drug-delivery/modulation platform enabling targeted gene upregulation.
|
$61.09M |
$3.03
+1.00%
|
|
CNM-Au8 and the CSN platform represent a drug delivery platform that directly underpins the company's therapeutic products.
|
$54.35M |
$6.05
-1.14%
|
|
Core POZ drug-delivery platform directly enabling long-acting, CNS-targeted therapeutics.
|
$52.93M |
$5.31
-0.38%
|
|
CPIX emphasizes differentiated drug delivery mechanisms (e.g., Sancuso transdermal patch) and extended-release formulations, mapping to the 'Drug Delivery Platforms' theme.
|
$51.62M |
$3.45
-2.27%
|
|
sEEG-based drug delivery system represents a drug delivery platform for localized therapeutic administration.
|
$47.33M |
$0.95
-7.77%
|
|
Tumor-activated/masked approach represents a Drug Delivery Platforms capability to localize activity and improve safety/efficacy.
|
$43.64M |
$0.84
-5.31%
|
|
IO Biotech describes the T-win platform as a drug delivery platform for cancer vaccines to stimulate T cells and modulate the tumor microenvironment.
|
$36.37M |
$0.55
-4.81%
|
|
Directly provides a proprietary drug-delivery platform (RaniPill GO/HC) for oral biologics.
|
$26.37M |
$0.46
-3.54%
|
|
Drug Delivery Platforms: rhCollagen scaffolds can function as localized delivery systems for regenerative signals.
|
$25.20M |
$2.20
-6.38%
|
|
Core platform technology for targeted radiotherapeutics (drug delivery via nanoliposomes) representing PSTV's REYOBIQ approach.
|
$24.42M |
$0.72
-7.07%
|
|
HT-001 is a topical drug formulation; BioLexa represents a Drug Delivery Platforms capability.
|
$20.87M |
$1.58
-5.39%
|
|
Certepetide functions as a drug delivery platform that enhances penetration and remodels the tumor microenvironment.
|
$20.38M |
$2.37
|
|
PolyPid's PLEX is a proprietary drug delivery platform enabling localized, prolonged release of APIs at the surgical site, core to the business.
|
$15.11M |
$3.15
-3.96%
|
|
Proprietary drug-delivery platform technology (TRRP/ODT) enabling extended-release and easier administration.
|
$14.56M |
$2.36
-7.45%
|
|
LungFit is described as a drug delivery platform for nitric oxide, i.e., a platform technology for NO delivery.
|
$11.78M |
$2.54
-5.58%
|
|
The company emphasizes proprietary drug formulations and delivery methods as a core moat, mapping to Drug Delivery Platforms.
|
$9.20M |
$0.70
-6.52%
|
|
Proprietary RNA delivery platform (TTX) that aims to enhance tumor/metastasis delivery of RNA therapeutics.
|
$8.81M |
$10.56
-1.45%
|
|
Adrulipase is delivered as a targeted GI capsule, reflecting a drug delivery platform approach.
|
$8.32M |
$5.24
+11.25%
|
|
Drug delivery platforms enabling oral delivery of biologics (TH023 via Soteria/Phloral).
|
$7.93M |
$2.98
-7.45%
|
|
Uses a proprietary Phospholipid Drug Conjugate (PDC) platform as a drug-delivery technology to target cancer cells.
|
$7.13M |
$4.64
-3.73%
|
|
K1.1 mRNA delivery via lipid nanoparticles suggests a drug delivery platform technology.
|
$7.06M |
$1.55
-6.63%
|
|
Helix transendocardial biotherapeutic delivery system constitutes a drug delivery platform for localized cell therapies.
|
$7.04M |
$1.36
+0.37%
|
|
DfuseRx drug delivery platform is the core technology enabling intratumoral administration and systemic immune effects.
|
$5.61M |
$0.30
-17.43%
|
|
InhiBET platform enables localized/topical drug delivery (VYN201), fitting Drug Delivery Platforms.
|
$5.53M |
$0.33
+5.00%
|
|
HyBryte and ThermoVax represent platform-based delivery approaches, aligning with Drug Delivery Platforms.
|
$5.48M |
$1.68
-5.08%
|
|
RedTail is an enveloped virus delivery system enabling systemic administration, i.e., a proprietary Drug Delivery Platform.
|
$4.11M |
$1.55
-1.90%
|
|
Utilizes intranasal and implantable drug delivery technologies, captured by Drug Delivery Platforms.
|
$2.52M |
$0.56
-16.31%
|
|
Northstrive Biosciences is pursuing a drug delivery platform via engineered probiotic therapies (EL-22/EL-32).
|
$2.10M |
$5.31
-0.56%
|
|
Drug Delivery Platforms: proprietary delivery technology (extended-release formulation) underpinning the CNS programs.
|
$1.73M |
$1.76
-4.35%
|
|
Proprietary drug-delivery platform potentially enabling targeted, RT-sensitizing therapies.
|
$1.67M |
$3.80
+6.74%
|
Loading industry metrics...
Loading comparison data...
